340383.png
340383.png

CD3/CD4/CD45三色荧光单克隆抗体

  • 商品品牌： 碧迪医疗
  • 分类： 生物试剂
  • Spec： 50T
  • 货期： 咨询
￥5136.00

描述

BD Tritest™ CD3 fluorescein isothiocyanate (FITC)/CD4 phycoerythrin (PE)/CD45 peridinin chlorophyll protein (PerCP) is a three-color direct immunofluorescence reagent for use with a suitably equipped flow cytometer to identify and determine the percentages and absolute counts of mature human T lymphocytes (CD3+) and helper/inducer (CD3+CD4+) T-lymphocytes subsets in erythrocyte-lysed whole blood. When used with Trucount™ tubes, absolute counts of these populations can be enumerated from a single tube.

BD Tritest reagent and Trucount tubes can be used with the FACS™ Loader.  The reagent can be used with or without an isotype control.

准备和存储

• Store the reagent at 2° to 8°C. Do not use after the expiration date shown on the label.

• Do not freeze the reagent or expose it to direct light during storage or incubation with cells. Keep the reagent vial dry.

• Store BD Trucount tubes in their original foil pouch at 2° to 25°C. To avoid potential condensation, open the pouch only after it has reached room temperature and carefully reseal the pouch immediately after removing a tube. Examine the desiccant each time you open the pouch. If the desiccant has turned from blue to lavender, discard the remaining tubes. An unopened pouch is stable until the expiration date shown on the packaging. Do not open and use tubes after this expiration date. Use tubes within 1 hour after removal from the foil pouch. Use remaining tubes within 1 month after opening the pouch.

碧迪医疗是一家全球化的医疗技术公司，通过改善医学发现方法、医疗诊断效果和护理质量以引领世界健康。碧迪医疗关注并支持每位一线医务工作者，致力于通过研发创新技术、服务和解决方案，帮助患者改善临床治疗，并帮助医护人员改进临床流程。碧迪医疗及其75,000名全球员工秉承高度的热情和信念，为临床医护人员提供安全、高效的护理给药流程，协助实验室科学家们更有效地诊断疾病，并提升科研人员研发新一代诊断及治疗疾病的能力。碧迪医疗在几乎所有国家均设有分支机构，与全球范围内的组织机构积极合作，携手应对最具挑战的全球健康问题。通过与客户的紧密协作，碧迪医疗以改善治疗结果，降低医疗成本，提升诊断效率为己任，帮助加强患者和医护人员的安全并扩大医疗可及性。

碧迪医疗于1994年正式派员在中国注册建立代表机构，开展对华业务。目前形成以上海为区域总部，在北京、广州、成都等城市均设有办事机构，拥有员工近4000人。迄今近30年间，碧迪医疗秉承“根植中国，服务中国”(In China, For China)的理念，致力于打造优质的本土化跨国医疗技术公司，总投资数亿美元，建设本土三大工厂，2个研发中心和1个客户服务中心，并且设置了客户体验中心、数家专业培训中心及实验室，以及2023年正式落成的首家综合性碧迪医疗大中华区创新中心等机构，积极践行健康中国2030，造福更多中国患者和医疗工作者，帮助推进医学事业的进步。